NYU Langone’S Perlmutter Cancer Center
Data support less aggressive approach before transplant in relapsed/refractory AML
NEW ORLEANS — Skipping intensive remission-induction chemotherapy prior to allogeneic hematopoietic stem cell transplant did not impact survival outcomes among patients with relapsed/refractory acute myeloid leukemia, according to a study.
Immunotherapy a ‘significant improvement’ for treatment of multiple myeloma
Despite being behind the curve for adoption of immunotherapy, the field of multiple myeloma has witnessed monumental advances in patient survival with the use of novel agents, according to a speaker at Chemotherapy Foundation Symposium.
Data show ‘critical need’ for universal genetic testing of patients with breast cancer
Universal germline genetic testing benefited patients with breast cancer and their physicians in implementing effective precision treatments and personalized disease management, according to study results published in JAMA Network Open.
Timing of pembrolizumab makes a difference in resectable melanoma
Neoadjuvant pembrolizumab extended event-free survival compared with adjuvant-only administration of the anti-PD-1 therapy among patients with resectable melanoma, according to phase 2 study results presented at ESMO Congress.
Cell therapy doubles survival, response rates in advanced melanoma
A single infusion of tumor-infiltrating lymphocytes more than doubled PFS, OS and complete response rates compared with ipilimumab among patients with advanced, unresectable melanoma, study results presented at ESMO Congress showed.
Olaparib regimen extends survival for certain women with advanced ovarian cancer
Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.
Daratumumab appears safe for patients with multiple myeloma, advanced renal insufficiency
CHICAGO — Daratumumab appeared safe for patients with multiple myeloma who had advanced renal insufficiency, according to study results presented at ASCO Annual Meeting.
Some older women with luminal A breast cancer can safely forgo radiotherapy, study shows
CHICAGO — Patients aged 55 years or older with low-grade luminal A breast cancer who receive endocrine therapy can safely avoid radiotherapy after breast-conserving surgery, according to a prospective study presented at ASCO Annual Meeting.
Triplet induction, autologous HSCT, lenalidomide maintenance extend PFS in multiple myeloma
CHICAGO — Lenalidomide, bortezomib and dexamethasone plus autologous stem cell transplantation and lenalidomide-based maintenance conferred a significant PFS benefit among patients with newly diagnosed multiple myeloma.
Shared decision-making required when choosing first-line regimen for PD-L1-high NSCLC
CHICAGO — Chemoimmunotherapy and immunotherapy alone conferred comparable benefit as first-line therapy for most patients with advanced non-small cell lung cancer and high PD-L1 expression, results presented at ASCO Annual Meeting showed.